devised CAR‐NK‐92 cells that secrete IL‐15 against CD123+ acute myeloid leukemia (AML).[70] The CAR‐NK‐92 cells demonstrated potent cytotoxicity in in vitro assessments, and within the peripheral blood of patient‐derived xenograft (PDX) models, they effectively eliminated CD123+ AML cells. Here, IL15 is linked to acute myeloid leukemia.